Significant Ownership of AbbVie Inc.

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for AbbVie Inc. focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Scott T. Reents - Scott T. Reents, Executive Vice President, Chief Financial Officer
Manager location
North Chicago, IL

Follow Filing Activity

Follow AbbVie Inc. and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of AbbVie Inc.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
XLO Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share 9% $3,304,348 4,347,826 AbbVie Inc. 11 Feb 2025

Schedules 13D/G Reported by AbbVie Inc.:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .